20:41 , Jan 18, 2019 |  BC Week In Review  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
23:21 , Jan 17, 2019 |  BC Extra  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
18:45 , Oct 20, 2017 |  BioCentury  |  Finance

Fast inflections

Longitude Capital joined Cydan Development Inc. ’s syndicate with the expectation that spinouts from the rare disease accelerator can deliver returns within three to five years. The company sources rare disease assets from academia, not-for-profits...
00:34 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Orphan drug accelerator Cydan raises $34M

Cydan Development Inc. (Cambridge, Mass.), which operates an accelerator that spins out rare genetic disease companies, raised $34 million on Oct. 17 in a round led by existing investor New Enterprise Associates (NEA). New investor...
22:58 , Oct 17, 2017 |  BC Extra  |  Financial News

Orphan drug accelerator Cydan raises $34M

Cydan Development Inc. (Cambridge, Mass.), which operates an accelerator that spins out rare genetic disease companies, raised $34 million in a round led by existing investor New Enterprise Associates (NEA). New investor Longitude Capital and...
18:34 , Jun 9, 2017 |  BioCentury  |  Regulation

New SOC in sickle cell?

If FDA follows ODAC’s recommendation to approve Endari L-glutamine from Emmaus Life Sciences Inc. , the candidate is likely to become the backbone of sickle cell therapy. On May 24, FDA’s Oncologic Drugs Advisory Committee...
17:34 , May 26, 2017 |  BC Week In Review  |  Clinical News

FDA grants IMR-687 rare pediatric disease designation

Imara Inc. (Cambridge, Mass.) said FDA granted rare pediatric disease designation to IMR-687 to treat sickle cell disease (SCD). Imara said it is the first SCD candidate to receive the designation from the agency. The...
23:48 , Feb 28, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cell-free assays A synaptosome-based assay of long-term synaptic potentiation could be used to screen therapies to treat AD. The assay involved isolating synaptosomes from frozen, postmortem parietal cortex samples from AD patients and unaffected...
19:59 , Dec 6, 2016 |  BC Week In Review  |  Clinical News

IMR-687: Ph I started

Imara began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate oral IMR-687 in about 42 healthy volunteers. Imara has exclusive, worldwide rights to IMR-687 from H. Lundbeck (see BioCentury, April 18 ). Imara Inc....
07:00 , Aug 4, 2016 |  BC Innovations  |  Finance

2Q16 Public-Private Partnership Roundup

A new consortia revival helped boost public-private partnerships (PPPs) in 2Q16 to the highest total in two years. Newly announced preclinically focused deals jumped 30% over the relatively sluggish first quarter, from 56 PPPs to...